Protek Medical Products Is Acquired by Aspen Surgical Products – Strenthens Aspen’s Broad Portfolio

“Protek Medical has a long, successful history of providing effective, easy-to-use disposable products that help address cross-contamination issues in the clinical environment,” said Jason Krieser, CEO of Aspen Surgical.

November 24, 2020

Protek Medical, based in California, is a leading global manufacturer of single-use ultrasonic probe covers and needle guides used in tissue biopsies, fluid aspiration, and vascular access procedures as well as protective covers for medical instruments and equipment.

Protek Medical has demonstrated a consistent track record of driving recurring revenue growth and innovation, fueled by best-in-class R&D capabilities. Protek has become a supplier of choice for leading OEMs in the ultrasound equipment space.

The acquisition of Protek strengthens Aspen’s broad portfolio of medical and patient & staff safety products sold into hospital and surgery center markets. This includes Protek’s patented Pull-Up™ probe cover technology, which helps support efficiency in the clinical environment.

“Protek Medical has a long, successful history of providing effective, easy-to-use disposable products that help address cross-contamination issues in the clinical environment,” said Jason Krieser, CEO of Aspen Surgical. “This line is clearly synergistic with our current manufacturing and commercial operations and it supports our mission to provide high quality single-use medical devices that improve safety and efficiency for the healthcare settings that we serve.”

“Protek is very excited to team up with Aspen Surgical,” said Protek CEO Rick Pruter. “This will not only broaden our customers’ access to consumable product offerings, but also expand our new product development opportunities. Aspen’s goals align directly with our vision of optimizing patient safety in the imaging market.”

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.